INmune Bio is pairing a quantum machine with AI to find diseases beyond Alzheimer’s that its drug candidate might help.

The Florida biotech takes on a pulmonary hypertension pipeline backed by Fairmount, with cash it says should last into 2029.

Immorta Bio says its AI-designed SenoMune-0257 prompts T cells to clear senescent cells, and plans first human evaluation ...

TimePie's Hebe Chen spotlights key developments from Shanghai, from therapeutic targets to China’s expanding clinical ...

A new review argues postpartum recovery may shape lifelong aging; a fandom health standard asks who helps mothers get there.

Niagen Bioscience’s new Niagen Plus vial comes pre-filled and needs no mixing. It is available via a telehealth platform from ...

Cognition Therapeutics wins a US patent on a new crystal form of zervimesine and has an FDA meeting on its Lewy body trial ...

Zealand Pharma and Generate Biomedicines will design multispecific proteins for metabolic disease, in a deal with nearly ...

Berlin keynote details Eos SENOLYTIX's pre-clinical results with mitochondrial-targeted geropeptide on healthspan and lifespan.

As its CEO takes the stage in Berlin, the company opens a window on its longest-lived treated mice – and the data behind them ...

Avaí Bio and Austrianova began work with Ospedale San Raffaele on protecting lab-grown insulin cells from the immune system.

Rona Therapeutics grants Roche worldwide rights to an ALK7-silencing candidate, with up to $1.06b in further milestones on ...